Literature DB >> 3626790

Biodistribution of GdCl3 and Gd-DTPA and their influence on proton magnetic relaxation in rat tissues.

J L Barnhart, N Kuhnert, D A Bakan, R N Berk.   

Abstract

The biodistribution and relative molar effectiveness of the ionic (GdCl3) and chelated (Gd-DTPA) forms of gadolinium (Gd) to enhance proton relaxation rates in rat kidney, liver and spleen were evaluated. Rats were given intravenous injections of either GdCl3 (100 mumol/kg) or Gd-DTPA (178 mumol/kg). Gd-DTPA was primarily contained in the vascular compartment and was quickly accumulated in the kidney after injection with a relaxivity of 4.3 sec-1 (mumol/g kidney)-1. It was eliminated quickly from the body with only 2% of the injected dose remaining after 120 min. After GdCl3 injection, Gd was found primarily in liver and spleen. It accumulated continuously reaching 72% of the injected does in these two tissues after 120 min. Despite this continuous increase in tissue Gd concentration, the relaxation rates showed saturation in liver and spleen. The results suggest that after GdCl3 was injected it distributed either in a protein bound form that was effective at causing relaxation or in a colloid form that was not effective. The biodistribution of GdCl3 was such that it was determined by the phagocytic action of the recticuloendothelial system on a colloid. The biodistribution and tissue relaxivity of Gd-DTPA suggest it will be a useful vascular MRI contrast agent. However, the usefulness of GdCl3 as an MRI contrast agent is limited not only by its acute toxicity but also by its saturable effect on tissue relaxation rates. Consequently, GdCl3 has only a modest influence on tissue relaxivity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3626790     DOI: 10.1016/0730-725x(87)90023-3

Source DB:  PubMed          Journal:  Magn Reson Imaging        ISSN: 0730-725X            Impact factor:   2.546


  10 in total

1.  Experimental studies investigating the pathophysiology of nephrogenic systemic fibrosis; what did we learn so far?

Authors:  Sameh K Morcos
Journal:  Eur Radiol       Date:  2010-09-17       Impact factor: 5.315

2.  Rational design of protein-based MRI contrast agents.

Authors:  Jenny J Yang; Jianhua Yang; Lixia Wei; Omar Zurkiya; Wei Yang; Shunyi Li; Jin Zou; Yubin Zhou; Anna L Wilkins Maniccia; Hui Mao; Fuqiang Zhao; Russell Malchow; Shumin Zhao; Julian Johnson; Xiaoping Hu; Eirik Krogstad; Zhi-Ren Liu
Journal:  J Am Chem Soc       Date:  2008-06-25       Impact factor: 15.419

3.  A USPIO doped gel phantom for R2* relaxometry.

Authors:  Gregory C Brown; Gary J Cowin; Graham J Galloway
Journal:  MAGMA       Date:  2016-07-19       Impact factor: 2.310

4.  In vivo stability and excretion of gadodiamide (GdDTPA-BMA), a hydrophilic gadolinium complex used as a contrast enhancing agent for magnetic resonance imaging.

Authors:  P T Normann; P A Hals
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Oct-Dec       Impact factor: 2.441

5.  Fibroblast response to gadolinium: role for platelet-derived growth factor receptor.

Authors:  Narasimharao Bhagavathula; Michael K Dame; Marissa DaSilva; William Jenkins; Muhammad N Aslam; Patricia Perone; James Varani
Journal:  Invest Radiol       Date:  2010-12       Impact factor: 6.016

Review 6.  Gadolinium in Medical Imaging-Usefulness, Toxic Reactions and Possible Countermeasures-A Review.

Authors:  Lennart Blomqvist; Gunnar F Nordberg; Valeria M Nurchi; Jan O Aaseth
Journal:  Biomolecules       Date:  2022-05-24

Review 7.  Exposure, metabolism, and toxicity of rare earths and related compounds.

Authors:  S Hirano; K T Suzuki
Journal:  Environ Health Perspect       Date:  1996-03       Impact factor: 9.031

Review 8.  Scleroderma-like fibrosing disorders.

Authors:  Francesco Boin; Laura K Hummers
Journal:  Rheum Dis Clin North Am       Date:  2008-02       Impact factor: 2.670

9.  Investigation of potential adverse central nervous system effects after long term oral administration of gadolinium in mice.

Authors:  Dominik Nörenberg; Felix Schmidt; Karin Schinke; Thomas Frenzel; Hubertus Pietsch; Armin Giese; Birgit Ertl-Wagner; Johannes Levin
Journal:  PLoS One       Date:  2020-04-23       Impact factor: 3.240

10.  Nephrogenic systemic fibrosis.

Authors:  Bhushan Madke; Uday Khopkar
Journal:  Indian Dermatol Online J       Date:  2011-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.